References
- Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentra-tion to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31 (7): 1054–1060.
- Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23–27.
- Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother. 2003; 52 (6): 893–898.
- Chuck SK, Raber SR, Rodvold KA, Areff D. National sur-vey of extended interval aminoglycoside dosing. Clin Infect Dis 2000; 30 (3): 433–439.
- Vanko JA, Brown BA, Fanikos J, Churchill W. Evaluation of implementing aminoglycoside dosing guidelines in a large ac-ademic medical center. Presented at the 39th ASHP Midyear Clinical Meeting and Exhibition, Orlando, FL; Dec 5-9, 2004.
- Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminogly-coside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39 (3): 650–655.
- Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommenda-tions for clinical practice. J Antimicrob Chemother 1997; 39: 677–686.
- Barza M, loannidis JP, Cappalleri JC, Lau J. Single or mul-tiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312 (10): 338–344.
- Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. An Intern Med 1996; 124 (8): 717:725.1°
- Wright AJ, Wilson WR, Matsumoto JY, et al. Influence of gentamicin dose size on efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococ-cal endocarditis. Antimicrob Agents Chemother 1982; 22 (6): 972–975.
- Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002; 49 (3): 437–444.
- Smyth A, Tan KK, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fi-brosis - the TOPIC study: a randomized controlled trial. Lancet 2005; 365 (9459): 547–558.
- Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997; 112: 1208–1213.
- Whithead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19: 303–309.
- Cockcroft DW, Gault MH. Prediction of creatinine clear-ance from serum creatinine. Nephron 1976; 16 (1): 31–41.
- Davis DA, Taylor-Vaisy A. Translating guidelines into prac-tice: A systematic review of theoretic concepts, practical experi-ence and research in the adoption of clinical practice guidelines. CMAJ 1997; 157 (4): 408–416.
- Anger KE, Szumita PM. Barriers to glucose control in the ICU. Pharmacotherapy 2006; 26 (2): 214–228.